Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-06-2016 | Review Article

Current status of PET imaging in Huntington’s disease

Authors: Gennaro Pagano, Flavia Niccolini, Marios Politis

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2016

Abstract

Purpose

To review the developments of recent decades and the current status of PET molecular imaging in Huntington’s disease (HD).

Methods

A systematic review of PET studies in HD was performed. The MEDLINE, Web of Science, Cochrane and Scopus databases were searched for articles in all languages published up to 19 August 2015 using the major medical subject heading “Huntington Disease” combined with text and key words “Huntington Disease”, “Neuroimaging” and “PET”. Only peer-reviewed, primary research studies in HD patients and premanifest HD carriers, and studies in which clinical features were described in association with PET neuroimaging results, were included in this review. Reviews, case reports and nonhuman studies were excluded.

Results

A total of 54 PET studies were identified and analysed in this review. Brain metabolism ([¹⁸F]FDG and [¹⁵O]H₂O), presynaptic ([¹⁸F]fluorodopa, [¹¹C]β-CIT and [¹¹C]DTBZ) and postsynaptic ([¹¹C]SCH22390, [¹¹C]FLB457 and [¹¹C]raclopride) dopaminergic function, phosphodiesterases ([¹⁸F]JNJ42259152, [¹⁸F]MNI-659 and [¹¹C]IMA107), and adenosine ([¹⁸F]CPFPX), cannabinoid ([¹⁸F]MK-9470), opioid ([¹¹C]diprenorphine) and GABA ([¹¹C]flumazenil) receptors were evaluated as potential biomarkers for monitoring disease progression and for assessing the development and efficacy of novel disease-modifying drugs in premanifest HD carriers and HD patients. PET studies evaluating brain restoration and neuroprotection were also identified and described in detail.

Conclusion

Brain metabolism, postsynaptic dopaminergic function and phosphodiesterase 10A levels were proven to be powerful in assessing disease progression. However, no single technique may be currently considered an optimal biomarker and an integrative multimodal imaging approach combining different techniques should be developed for monitoring potential neuroprotective and preventive treatment in HD.

Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov Disord. 2012;27:1083–91.CrossRefPubMed

The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72:971–83.CrossRef

Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10(4):204–16.CrossRefPubMed

Scherzinger E, Sittler A, Schweiger K, Heiser V, Lurz R, Hasenbank R, et al. Self-assembly of polyglutamine containing huntingtin fragments into amyloid-like fibrils: implications for Huntington disease pathology. Proc Natl Acad Sci U S A. 1999;96:4604–9.CrossRefPubMedPubMedCentral

Langbehn DR, Hayden MR, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group. CAG repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:397–408.PubMedPubMedCentral

Reilmann R, Leavitt BR, Ross CA. Diagnostic criteria for Huntington’s disease based on natural history. Mov Disord. 2014;29:1335–41.CrossRefPubMed

Rüb U, Vonsattel JP, Heinsen H, Korf HW. The neuropathology of Huntington´s disease: classical findings, recent developments and correlation to functional neuroanatomy. Adv Anat Embryol Cell Biol. 2015;217:1–146.CrossRefPubMed

Politis M, Piccini P. Positron emission tomography imaging in neurological disorders. J Neurol. 2012;259(9):1769–80.CrossRefPubMed

Politis M. Neuroimaging in Parkinson disease: from research setting to clinical practice. Nat Rev Neurol. 2014;10(12):708–22.CrossRefPubMed

10.

Loane C, Politis M. Positron emission tomography neuroimaging in Parkinson’s disease. Am J Transl Res. 2011;3(4):323–41.PubMedPubMedCentral

11.

Rocchi L, Niccolini F, Politis M. Recent imaging advances in neurology. J Neurol. 2015;262(9):2182–94.CrossRefPubMed

12.

Niccolini F, Politis M. Neuroimaging in Huntington’s disease. World J Radiol. 2014;6(6):301–12.CrossRefPubMedPubMedCentral

13.

Sokoloff L. Localization of functional activity in the central nervous system by measurement of glucose utilization with radioactive deoxyglucose. J Cereb Blood Flow Metab. 1981;1:7–36.CrossRefPubMed

14.

Bartenstein P, Weindl A, Spiegel S, Boecker H, Wenzel R, Ceballos-Baumann AO, et al. Central motor processing in Huntington’s disease. A PET study. Brain. 1997;120(Pt 9):1553–67.CrossRefPubMed

15.

Weeks RA, Ceballos-Baumann A, Piccini P, Boecker H, Harding AE, Brooks DJ. Cortical control of movement in Huntington’s disease. A PET activation study. Brain. 1997;120(Pt 9):1569–78.CrossRefPubMed

16.

Lepron E, Péran P, Cardebat D, Démonet JF. A PET study of word generation in Huntington’s disease: effects of lexical competition and verb/noun category. Brain Lang. 2009;110:49–60.CrossRefPubMed

17.

Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington’s disease. Brain. 1996;119(Pt 6):2085–95.CrossRefPubMed

18.

Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, Riege WH, et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington’s disease. N Engl J Med. 1987;316:357–62.CrossRefPubMed

19.

Kuwert T, Lange HW, Langen KJ, Herzog H, Aulich A, Feinendegen LE. Cortical and subcortical glucose consumption measured by PET in patients with Huntington’s disease. Brain. 1990;113(Pt 5):1405–23.CrossRefPubMed

20.

Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, et al. PET scan investigations of Huntington’s disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol. 1986;20:296–303.CrossRefPubMed

21.

Berent S, Giordani B, Lehtinen S, Markel D, Penney JB, Buchtel HA, et al. Positron emission tomographic scan investigations of Huntington’s disease: cerebral metabolic correlates of cognitive function. Ann Neurol. 1988;23:541–6.CrossRefPubMed

22.

Hayden MR, Martin WR, Stoessl AJ, Clark C, Hollenberg S, Adam MJ, et al. Positron emission tomography in the early diagnosis of Huntington’s disease. Neurology. 1986;36:888–94.CrossRefPubMed

23.

Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease. J Nucl Med. 2006;47:215–22.PubMed

24.

Ciarmiello A, Giovacchini G, Orobello S, Bruselli L, Elifani F, Squitieri F. 18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size. Eur J Nucl Med Mol Imaging. 2012;39:1030–6.CrossRefPubMed

25.

Feigin A, Leenders KL, Moeller JR, Missimer J, Kuenig G, Spetsieris P, et al. Metabolic network abnormalities in early Huntington’s disease: an [18F]FDG PET study. J Nucl Med. 2001;42:1591–5.

26.

Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, et al. Thalamic metabolism and symptom onset in preclinical Huntington’s disease. Brain. 2007;130:2858–67.CrossRefPubMedPubMedCentral

27.

Eidelberg D, Surmeier DJ. Brain networks in Huntington disease. J Clin Invest. 2011;121:484–92.CrossRefPubMedPubMedCentral

28.

Tang CC, Feigin A, Ma Y, Habeck C, Paulsen JS, Leenders KL, et al. Metabolic network as a progression biomarker of premanifest Huntington’s disease. J Clin Invest. 2013;123:4076–88.CrossRefPubMedPubMedCentral

29.

Schrag A, Quinn N. Disorders of the basal ganglia and their modern management. J R Coll Physicians Lond. 1999;33(4):323–7.PubMed

30.

Day M, Wokosin D, Plotkin JL, Tian X, Surmeier DJ. Differential excitability and modulation of striatal medium spiny neuron dendrites. J Neurosci. 2008;28(45):11603–14.CrossRefPubMedPubMedCentral

31.

Martin WR, Hayden MR. Cerebral glucose and dopa metabolism in movement disorders. Can J Neurol Sci. 1987;14(3 Suppl):448–51.PubMed

32.

Leenders KL, Frackowiak RS, Quinn N, Marsden CD. Brain energy metabolism and dopaminergic function in Huntington’s disease measured in vivo using positron emission tomography. Mov Disord. 1986;1:69–77.CrossRefPubMed

33.

Ginovart N, Lundin A, Farde L, Halldin C, Backman L, Swahn CG, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington’s disease. Brain. 1997;120(Pt 3):503–14.CrossRefPubMed

34.

Bohnen NI, Koeppe RA, Meyer P, Ficaro E, Wernette K, Kilbourn MR, et al. Decreased striatal monoaminergic terminals in Huntington disease. Neurology. 2000;54(9):1753–9.CrossRefPubMed

35.

Esmaeilzadeh M, Farde L, Karlsson P, Varrone A, Halldin C, Waters S, et al. Extrastriatal dopamine D(2) receptor binding in Huntington’s disease. Hum Brain Mapp. 2011;32:1626–36.CrossRefPubMed

36.

Sedvall G, Karlsson P, Lundin A, Anvret M, Suhara T, Halldin C, et al. Dopamine D1 receptor number – a sensitive PET marker for early brain degeneration in Huntington’s disease. Eur Arch Psychiatry Clin Neurosci. 1994;243:249–55.CrossRefPubMed

37.

Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, et al. Huntington’s disease progression. PET and clinical observations. Brain. 1999;122(Pt 12):2353–63.CrossRefPubMed

38.

van Oostrom JC, Maguire RP, Verschuuren-Bemelmans CC, Veenma-van der Duin L, Pruim J, Roos RA, et al. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology. 2005;65:941–3.CrossRefPubMed

39.

Turjanski N, Weeks R, Dolan R, Harding AE, Brooks DJ. Striatal D1 and D2 receptor binding in patients with Huntington’s disease and other choreas. A PET study. Brain. 1995;118(Pt 3):689–96.CrossRefPubMed

40.

Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington’s disease: a PET study. Brain. 2003;126:1127–35.CrossRefPubMed

41.

Bäckman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L. Cognitive deficits in Huntington’s disease are predicted by dopaminergic PET markers and brain volumes. Brain. 1997;120(Pt 12):2207–17.CrossRefPubMed

42.

Pavese N, Politis M, Tai YF, Barker RA, Tabrizi SJ, Mason SL, et al. Cortical dopamine dysfunction in symptomatic and premanifest Huntington’s disease gene carriers. Neurobiol Dis. 2010;37:356–61.CrossRefPubMed

43.

Lawrence AD, Weeks RA, Brooks DJ, Andrews TC, Watkins LH, Harding AE, et al. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington’s disease. Brain. 1998;121(Pt 7):1343–55.CrossRefPubMed

44.

Politis M, Pavese N, Tai YF, Tabrizi SJ, Barker RA, Piccini P. Hypothalamic involvement in Huntington’s disease: an in vivo PET study. Brain. 2008;131:2860–9.CrossRefPubMed

45.

Antonini A, Leenders KL, Eidelberg D. [11C]raclopride-PET studies of the Huntington’s disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol. 1998;43:253–5.CrossRefPubMed

46.

van Dijk G, van Heijningen S, Reijne AC, Nyakas C, van der Zee EA, Eisel UL. Integrative neurobiology of metabolic diseases, neuroinflammation, and neurodegeneration. Front Neurosci. 2015;9:173.PubMedPubMedCentral

47.

Politis M, Su P, Piccini P. Imaging of microglia in patients with neurodegenerative disorders. Front Pharmacol. 2012;3:96.CrossRefPubMedPubMedCentral

48.

Nakanishi H. Microglial functions and proteases. Mol Neurobiol. 2003;27:163–76.CrossRefPubMed

49.

Hatano K, Sekimata K, Yamada T, Abe J, Ito K, Ogawa M, et al. Radiosynthesis and in vivo evaluation of two imidazopyridineacetamides, [(11)C]CB184 and [(11)C]CB190, as a PET tracer for 18 kDa translocator protein: direct comparison with [(11)C](R)-PK11195. Ann Nucl Med. 2015;29(4):325–35.CrossRefPubMed

50.

Guo Q, Owen DR, Rabiner EA, Turkheimer FE, Gunn RN. Identifying improved TSPO PET imaging probes through biomathematics: the impact of multiple TSPO binding sites in vivo. Neuroimage. 2012;60(2):902–10. doi:10.1016/j.neuroimage.2011.12.078.CrossRefPubMedPubMedCentral

51.

Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA, et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology. 2006;66:1638–43.CrossRefPubMed

52.

Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Microglial activation in presymptomatic Huntington’s disease gene carriers. Brain. 2007;130:1759–66.CrossRefPubMed

53.

Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington’s disease: a multimodal imaging study. Hum Brain Mapp. 2011;32:258–70.CrossRefPubMed

54.

Politis M, Lahiri N, Niccolini F, Su P, Wu K, Giannetti P, et al. Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington’s disease gene carriers. Neurobiol Dis. 2015;83:115–21. doi:10.1016/j.nbd.2015.08.011.CrossRefPubMed

55.

Nishi A, Kuroiwa M, Miller DB, O'Callaghan JP, Bateup HS, Shuto T, et al. Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci. 2008;28:10460–71.CrossRefPubMedPubMedCentral

56.

Girault JA. Integrating neurotransmission in striatal medium spiny neurons. Adv Exp Med Biol. 2012;970:407–29.CrossRefPubMed

57.

Giampa C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington’s disease. PLoS One. 2010;5(10):e13417.

58.

Hebb AL, Robertson HA, Denovan-Wright EM. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington’s disease transgenic mice prior to the onset of motor symptoms. Neuroscience. 2004;123:967–81.CrossRefPubMed

59.

Ahmad R, Bourgeois S, Postnov A, Schmidt ME, Bormans G, Van Laere K, et al. PET imaging shows loss of striatal PDE10A in patients with Huntington disease. Neurology. 2014;82(3):279–81.CrossRefPubMed

60.

Russell DS, Barret O, Jennings DL, Friedman JH, Tamagnan GD, Thomae D, et al. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease. JAMA Neurol. 2014;71(12):1520–8.CrossRefPubMed

61.

Niccolini F, Haider S, Marques T, Muhlert N, Tziortzi A, Searle G, et al. Altered PDE10A expression detectable early before symptomatic onset in Huntington’s disease. Brain. 2015;138:3016–29. doi:10.1093/brain/awv214.CrossRefPubMed

62.

Gianfriddo M, Melani A, Turchi D, Giovannini MG, Pedata F. Adenosine and glutamate extracellular concentrations and mitogen activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiol Dis. 2004;17(1):77–88.CrossRefPubMed

63.

Bauer A, Zilles K, Matusch A, Holzmann C, Riess O, von Horsten S. Regional and subtype selective changes of neurotransmitter receptor density in a rat transgenic for the Huntington’s disease mutation. J Neurochem. 2005;94(3):639–50.CrossRefPubMed

64.

Matusch A, Saft C, Elmenhorst D, Kraus PH, Gold R, Hartung HP, et al. Cross sectional PET study of cerebral adenosine A1 receptors in premanifest and manifest Huntington’s disease. Eur J Nucl Med Mol Imaging. 2014;41(6):1210–20.CrossRefPubMed

65.

Herkenham M, Lynn AB, de Costa BR, Richfield EK. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 1991;547:267–74.CrossRefPubMed

66.

Glass M, Brotchie JM, Maneuf YP. Modulation of neurotransmission by cannabinoids in the basal ganglia. Eur J Neurosci. 1997;9:199–203.CrossRefPubMed

67.

Glass M, Dragunow M, Faull RL. The pattern of neurodegeneration in Huntington’s disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington’s disease. Neuroscience. 2000;97:505–19.CrossRefPubMed

68.

Whitehouse PJ, Trifiletti RR, Jones BE, Folstein S, Price DL, Snyder SH, et al. Neurotransmitter receptor alterations in Huntington’s disease: autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes. Ann Neurol. 1985;18(2):202–10.CrossRefPubMed

69.

Reisine TD, Wastek GJ, Speth RC, Bird ED, Yamamura HI. Alterations in the benzodiazepine receptor of Huntington’s diseased human brain. Brain Res. 1979;165(1):183–7.CrossRefPubMed

70.

Ribac CE, Vaughn JE, Roberts E. The GABA neurons and their axon terminals in rat corpus striatum as demonstrated by GAD immunocytochemistry. J Comp Neurol. 1979;187:261–84.CrossRef

71.

Holthoff VA, Koeppe RA, Frey KA, Penney JB, Markel DS, Kuhl DE, et al. Positron emission tomography measures of benzodiazepine receptors in Huntington’s disease. Ann Neurol. 1993;34(1):76–81.CrossRefPubMed

72.

Künig G, Leenders KL, Sanchez-Pernaute R, Antonini A, Vontobel P, Verhagen A, et al. Benzodiazepine receptor binding in Huntington’s disease: [11C]flumazenil uptake measured using positron emission tomography. Ann Neurol. 2000;47(5):644–8.CrossRefPubMed

73.

Van Laere K, Casteels C, Dhollander I, Goffin K, Grachev I, Bormans G, et al. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J Nucl Med. 2010;51:1413–7.CrossRefPubMed

74.

Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, et al. Mutant huntingtin’s effects on striatal gene expression in mice recapitulate changes observed in human Huntington’s disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet. 2007;16:1845–61.CrossRefPubMed

75.

Albin RL, Reiner A, Anderson KD, Dure 4th LS, Handelin B, Balfour R, et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington’s disease. Ann Neurol. 1992;31(4):425–30.CrossRefPubMed

76.

Seizinger BR, Liebisch DC, Kish SJ, Arendt RM, Hornykiewicz O, Herz A. Opioid peptides in Huntington's disease: alterations in prodynorphin and proenkephalin system. Brain Res. 1986;378:405–8.CrossRefPubMed

77.

Weeks RA, Cunningham VJ, Piccini P, Waters S, Harding AE, Brooks DJ. 11C-diprenorphine binding in Huntington’s disease: a comparison of region of interest analysis with statistical parametric mapping. J Cereb Blood Flow Metab. 1997;17:943–9.CrossRefPubMed

78.

Ooms M, Rietjens R, Rangarajan JR, Vunckx K, Valdeolivas S, Maes F, et al. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice. Neurobiol Aging. 2014;35(12):2858–69.CrossRefPubMed

79.

Shin H, Kim MH, Lee SJ, Lee KH, Kim MJ, Kim JS, et al. Decreased metabolism in the cerebral cortex in early-stage Huntington’s disease: a possible biomarker of disease progression? Int J Clin Neuropsychol. 2013;9:21–5.

80.

Reiner A, Albin RL, Anderson KD, D’Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A. 1988;85:5733–7.CrossRefPubMedPubMedCentral

81.

Russell D, Jennings D, Barret O, Tamagnan G, Carroll V, Alagille D, et al. Longitudinal assessment of PDE10 in Huntington disease (HD) using [18F]MNI-659 PET imaging. J Nucl Med. 2015;56 Suppl 3:87.

82.

Sabuncu MR, Desikan RS, Sepulcre J, Yeo BT, Liu H, Schmansky NJ, et al. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol. 2011;68:1040–8.CrossRefPubMedPubMedCentral

83.

Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante RJ, Salat DH, et al. Regional and progressive thinning of the cortical ribbon in Huntington’s disease. Neurology. 2002;58:695–701.CrossRefPubMed

84.

Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, et al. Cerebral cortex and the clinical expression of Huntington’s disease: complexity and heterogeneity. Brain. 2008;131:1057–68.CrossRefPubMedPubMedCentral

85.

Reading SA, Dziorny AC, Peroutka LA, Schreiber M, Gourley LM, Yallapragada V, et al. Functional brain changes in presymptomatic Huntington’s disease. Ann Neurol. 2004;55:879–83.CrossRefPubMed

86.

Rosser AE, Barker RA, Harrower T, Watts C, Farrington M, Ho AK, et al. Unilateral transplantation of human primary fetal tissue in four patients with Huntington’s disease: NESTUK safety report ISRCTN no 36485475. J Neurol Neurosurg Psychiatry. 2002;73:678–85.CrossRefPubMedPubMedCentral

87.

Furtado S, Sossi V, Hauser RA, Samii A, Schulzer M, Murphy CB, et al. Positron emission tomography after fetal transplantation in Huntington’s disease. Ann Neurol. 2005;58:331–7.CrossRefPubMed

88.

Barker RA, Mason SL, Harrower TP, Swain RA, Ho AK, Sahakian BJ, et al. The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington’s disease. J Neurol Neurosurg Psychiatry. 2013;84:657–65.CrossRefPubMedPubMedCentral

89.

Bachoud-Lévi AC, Rémy P, Nguyen JP, Brugières P, Lefaucheur JP, Bourdet C, et al. Motor and cognitive improvements in patients with Huntington’s disease after neural transplantation. Lancet. 2000;356:1975–9.CrossRefPubMed

90.

Gaura V, Bachoud-Lévi AC, Ribeiro MJ, Nguyen JP, Frouin V, Baudic S, et al. Striatal neural grafting improves cortical metabolism in Huntington’s disease patients. Brain. 2004;127:65–72.CrossRefPubMed

91.

Politis M, Piccini P. Brain imaging after neural transplantation. Prog Brain Res. 2010;184:193–203.CrossRefPubMed

92.

Politis M. Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson’s disease. BMC Med. 2011;9:50.CrossRefPubMedPubMedCentral

93.

Squitieri F, Orobello S, Cannella M, Martino T, Romanelli P, Giovacchini G, et al. Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. Eur J Nucl Med Mol Imaging. 2009;36(7):1113–20.CrossRefPubMed

94.

Esmaeilzadeh M, Kullingsjö J, Ullman H, Varrone A, Tedroff J. Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with Huntington disease. Clin Neuropharmacol. 2011;34(3):95–100.CrossRefPubMed

95.

Hjermind LE, Law I, Jønch A, Stokholm J, Nielsen JE. Huntington’s disease: effect of memantine on FDG-PET brain metabolism? J Neuropsychiatry Clin Neurosci. 2011;23(2):206–10.CrossRefPubMed

Title: Current status of PET imaging in Huntington’s disease
Authors: Gennaro Pagano
Flavia Niccolini
Marios Politis
Publication date: 01-06-2016
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3324-6

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Current status of PET imaging in Huntington’s disease

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2016

Is dopamine transporter invariably impaired at the time of diagnosis in dementia with Lewy bodies?

Noninferior response in BRAFV600E mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy

The Pathophysiologic Basis of Nuclear Medicine, Third Edition, Abdelhamid H. Elgazzar, Ed.

Pilot prospective evaluation of 18F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer

Rudy A.J.O. Dierckx, Andreas Otte, Erik F.J. de Vries, Aren van Waarde (eds); guest editor Klaus L. Leenders: PET and SPECT in Neurology

Metabotropic glutamate receptor 5 – a promising target in drug development and neuroimaging